Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences 1st-Ever Study Evaluating DehydraTECH-CBD’s Effect on Diabetes

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that study program DIAB-A22-1 is expected to begin on schedule today. According to the announcement, this is Lexaria’s first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol (“CBD”) may potentially have therapeutic utility against diabetes. The company has evidenced the safety and efficacy of DehydraTECH-CBD in human hypertension studies. Strong connections exist between heart disease, hypertension and diabetes, with hypertension twice as frequent in diabetics and hypertensive patients at greater risk of developing diabetes. Diabetes, which prevents the body from making enough insulin and results in abnormal blood sugar levels, is the seventh largest cause of death in the U.S. and there is currently no cure. Investigation of CBD related to diabetes is in early stages with some areas of ongoing research. CBD has shown some ability to reduce the incidence of diabetes in mice.

To view the full press release, visit https://ibn.fm/5r97e

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in Lexaria Bioscience Corp. LEXX. Bookmark the permalink.

Comments are closed.